Rallybio in joint venture with UK firm
The Farmington biotech startup Rallybio reports it is working on drug discovery with Exscientia an artificial intelligence company in the United Kingdom. Steve Uden, chief...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
The Farmington biotech startup Rallybio reports it is working on drug discovery with Exscientia an artificial intelligence company in the United Kingdom. Steve Uden, chief...
“We continued to advance our complement factor D inhibitors in the second quarter of 2019 by efficiently executing on our global development and regulatory strategies,...
Scientists and principals at KLEO Pharmaceuticals, on the third floor of 25 Science Park, were on hand recently to receive Sen. Chris Murphy’s Innovator of...
Shoreline Biome has announced partnerships with six international distributors. The distributors will sell the company’s microbiome kits and other products to companies and research organizations in...
The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) awarded Tangen Biosciences, Inc. the second phase of a contract...
A newly created accelerator program for medical technology and digital health startups is accepting applications for its first cohort of companies. The accelerator, a venture...
Lewis Bender is founder, president and CEO of Intenisty Therapeutics. Hee invented the company’s proprietary platform technology — DuseRx — conducting the initial chemistry in his...
UConn Health’s Leslie M. Loew, professor of cell biology and computer science and engineering, has received $1.3 million from the National Institutes of Health to...
Antibodies are large proteins that can grab onto and neutralize disease-causing microorganisms. Sometimes antibodies get confused, and grab onto harmless molecules from things like peanuts...
Assembly Biosciences reports the initiation of dosing in a Phase 1b clinical trial to evaluate ABI-M201 (M201) in patients with mildly to moderately active ulcerative...